Today EBX announced positive results from its Phase 1b clinical trial evaluating EBX-102, the Company’s next-generation oral full-spectrum microbiome product, in patients with liver cirrhosis.

EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients. Ph2b trial in IBS-C initiating in H2 2025 to confirm efficacy

Today we announced that results from our IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025.

Today we announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA.

EnteroBiotix Limited, a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced positive initial results with EBX-102-02, the Company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase 2a clinical trial in adults with irritable bowel syndrome with constipation (IBS-C).

122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 TrIuMPH trial assessing EBX-102-02. EnteroBiotix completed enrolment ahead of its planned schedule, dosing 62 participants with constipation predominant IBS and 60 participants with diarrhoea predominant IBS

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease

EnteroBiotix will be attending BIO Europe, Stockholm on 4-6 November 2024.

EnteroBiotix will be attending BIO Future, New York on 28-30 October 2024.

EnteroBiotix will be attending Microbiome Movement DDS, Boston on 10-12 July 2024.

EnteroBiotix will be attending Bio International Convention, 3-6 June 2024.

EnteroBiotix will be attending BioEquity Europe 2024, San Sebastian on 12-14 May 2024.

EnteroBiotix will be attending LSX World Congress, London on 29/30 April 2024.

EnteroBiotix will be attending BioTrinity, London on 23/24 April 2024.

EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

EnteroBiotix announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.

EnteroBiotix, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

Our CEO Dr James McIlroy presents at BioEquity covering the potential of our premier full-spectrum, microbiome product platform which prevents and treats disease through the restoration and enhancement of gut microbial ecology.

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

Modern Medicine publishes informative article on the clinical benefits of modulating the microbiome authored by our CEO Dr James McIlroy. In the article Dr McIlroy discusses the clinical benefits of modulating the microbiome, which are leading to new medical products and inspiring a behavioral shift in gut health.